Nicotinamide-N-oxide

CAS No. 1986-81-8

Nicotinamide-N-oxide( —— )

Catalog No. M13105 CAS No. 1986-81-8

Nicotinamide N - oxide is niacin related compounds, used in the study of nicotinic acid related granulocyte differentiation mechanism.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 30 In Stock
100MG 43 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Nicotinamide-N-oxide
  • Note
    Research use only, not for human use.
  • Brief Description
    Nicotinamide N - oxide is niacin related compounds, used in the study of nicotinic acid related granulocyte differentiation mechanism.
  • Description
    Nicotinamide N - oxide is niacin related compounds, used in the study of nicotinic acid related granulocyte differentiation mechanism.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    c-Myc
  • Recptor
    c-Myc
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1986-81-8
  • Formula Weight
    138.12
  • Molecular Formula
    C6H6N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    Limited solubility
  • SMILES
    NC(=O)C1=C[N+]([O-])=CC=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tian YJ, et al. Br J Nutr. 2014 May;111(9):1594-60
molnova catalog
related products
  • EN4 MYC inhibitor

    EN4 MYC inhibitor is a covalent ligand that targets cysteine 171 (C171) of MYC.

  • BET bromodomain inhi...

    CPI-0610 is a potent, selective, and cell-active BET bromodomain inhibitor CPI-0610 inhibits BRD4-BD1 with IC50 of 39 nM in time-resolved fluorescence energy transfer (TR-FRET ) binding assay.

  • APTO-253

    APTO-253 inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through the induction of the KLF4 tumor suppressor.APTO-253 (5 μM) induces KLF4 expression and enhances apoptosis induced by NSC 119875 in both SKOV3 and OVCAR3 cells.